Related references
Note: Only part of the references are listed.Rational Approaches for the Design of Effective Human Immunodeficiency Virus Type 1 Nonnucleoside Reverse Transcriptase Inhibitors
Sergio R. Ribone et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2011)
Effectiveness and Safety of Tenofovir Gel, an Antiretroviral Microbicide, for the Prevention of HIV Infection in Women
Quarraisha Abdool Karim et al.
SCIENCE (2010)
Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies
Filippo Canducci et al.
AIDS (2009)
Human Immunodeficiency Virus Type 1 Isolates with the Reverse Transcriptase (RT) Mutation Q145M Retain Nucleoside and Nonnucleoside RT Inhibitor Susceptibility
Vici Varghese et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Reverse Transcriptase Inhibitors as Potential Colorectal Microbicides
Carolina Herrera et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Human Immunodeficiency Virus Type 1 Recombinant Reverse Transcriptase Enzymes Containing the G190A and Y181C Resistance Mutations Remain Sensitive to Etravirine
Hongtao Xu et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Quantitating the Multiplicity of Infection with Human Immunodeficiency Virus Type 1 Subtype C Reveals a Non-Poisson Distribution of Transmitted Variants
M. -R. Abrahams et al.
JOURNAL OF VIROLOGY (2009)
Inflammatory Genital Infections Mitigate a Severe Genetic Bottleneck in Heterosexual Transmission of Subtype A and C HIV-1
Richard E. Haaland et al.
PLOS PATHOGENS (2009)
Antiretroviral drug-based microbicides to prevent HIV-1 sexual transmission
Per Johan Masse et al.
ANNUAL REVIEW OF MEDICINE (2008)
Identification and characterisation of transmitted and early founder virus envelopes in primary HIV-1 infection
Brandon F. Keele et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Transient antiretroviral therapy selecting for common HIV-1 mutations substantially accelerates the appearance of rare mutations
Tinevimbo Shiri et al.
THEORETICAL BIOLOGY AND MEDICAL MODELLING (2008)
The-incidence of HIV drug resistance and its impact on progression of HIV disease among antiretroviral-naive participants started on three different antiretroviral therapy strategies
Michael J. Kozal et al.
HIV CLINICAL TRIALS (2007)
Differential Drug Resistance Acquisition in HIV-1 of Subtypes B and C
Esmeralda A. J. M. Soares et al.
PLOS ONE (2007)
Structural insights into mechanisms of non-nucleoside drug resistance for HIV-1 reverse transcriptases mutated at codons 101 or 138
Jingshan Ren et al.
FEBS JOURNAL (2006)
Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies
Ting-Chao Chou
PHARMACOLOGICAL REVIEWS (2006)
Is HIV drug resistance a limiting factor in the development of anti-HIV NNRTI and NRTI-based vaginal microbicide strategies?
Jorge Martinez et al.
ANTIVIRAL RESEARCH (2006)
Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe:: Implications for clinical management
AMJ Wensing et al.
JOURNAL OF INFECTIOUS DISEASES (2005)
Gln145Met/leu changes in human immunodeficiency virus type 1 reverse transcriptase confer resistance to nucleoside and nonnucleoside analogs and impair virus replication
S Paolucci et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities
HS Weinstock et al.
JOURNAL OF INFECTIOUS DISEASES (2004)
Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants
K Das et al.
JOURNAL OF MEDICINAL CHEMISTRY (2004)
Virus population homogenization following acute human immunodeficiency virus type 1 infection
GH Learn et al.
JOURNAL OF VIROLOGY (2002)
Potency of nonnucleoside reverse transcriptase inhibitors (NNRTIs) used in combination with other human immunodeficiency virus NNRTIs, NRTIs, or protease inhibitors
RW King et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2002)
Infectious DNA clone of HIV type 1 A/G recombinant (CRF02_AG) replicable in peripheral blood mononuclear cells
M Takahoko et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2001)
Share Paper
